ClinicalTrials.gg
RecruitingNCT07582887Updated May 13, 2026

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

An observational study in Breast Cancer, Metastatic Breast Cancer and Drug-Related Side Effects and Adverse Reactions, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Observational

How we know · 8 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
77th of 97
70 · median 200
Started
2025
with 58 others
Observational
97 of 905
27 open now
Primary completion
2026-12
later than 110 of 284 live
Registered
894th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 77th largest by planned enrollment of the 97 observational ones that give a count, is one of 59 that started in 2025, is one of 97 observational ones, reaches primary completion later than 110 of the 284 other live ones, and was the 894th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The metabolism of anticancer drugs is influenced by genetic variants that affect their bioavailability and toxicity. In the case of antibody-drug conjugates (ADCs), such as sacituzumab-govitecan (SG), trastuzumab-deruxtecan (T-DXd), and datopotamab-deruxtecan (Dato-DXd), the enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) plays a central role in the glucuronidation and elimination of their cytotoxic components. In particular, the metabolism of SN-38, the active metabolite of irinotecan and SG, is highly influenced by variants in UGT1A1, leading to drug accumulation and the development of severe toxicities. Patients with variants such as UGT1A1*28 (rs3064744) and UGT1A1*6 (rs4148323) exhibit reduced enzyme activity, increasing the risk of neutropenia and severe diarrhea.

The relevance of UGT1A1 is not limited to sacituzumab-govitecan; its role in the elimination of camptothecin derivatives suggests it could also impact the toxicity of trastuzumab-deruxtecan and datopotamab-deruxtecan, which contain deruxtecan, a cytotoxic agent 10 times more potent than irinotecan. Despite strong evidence linking the UGT1A1 genotype to irinotecan toxicity, there are currently no established pharmacogenetic recommendations for antidiuretic peptides (ADCs) in metastatic breast cancer.

03

Conditions studied

  • Breast Cancer
  • Metastatic Breast Cancer
  • Drug-Related Side Effects and Adverse Reactions
  • Pharmacogenetic Variant

Keywords

  • UGT1A1
  • Genetic Variants
  • Toxicity
  • polymorphism
  • Breast Cancer
  • Sacituzumab Govitecan
  • Trastuzumab Deruxtecan
  • Datopotamab Deruxtecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with early, locally advanced, or metastatic breast cancer treated with antibody-drug conjugates in a real-world clinical setting at a single tertiary hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older.
  • Patients diagnosed with breast cancer starting or undergoing treatment with Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan.
  • Provision of signed for the genetic study.

Exclusion criteria

Exclusion Criteria:

  • Patients who are ultimately not treated with the specified Antibody-Drug Conjugates.
  • Refusal to provide for genetic analysis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
70 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Patients undergoing treatment with sacituzumab govitecan

    Standard clinical dose of sacituzumab govitecan administered as per routine clinical practice.

    Drug: Sacituzumab Govitecan

  • Patients undergoing treatment with trastuzumab-deruxtecan

    Standard clinical dose of trastuzumab-deruxtecan administered as per routine clinical practice.

    Drug: Trastuzumab deruxtecan

  • Patients undergoing treatment with datopotamab deruxtecan

    Standard clinical dose of datopotamab deruxtecan administered as per routine clinical practice.

    Drug: Datopotamab Deruxtecan

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Severe Drug-Related Toxicities (Grade ≥ 3)

    Number of patients experiencing severe hematological or gastrointestinal toxicities (defined as Grade 3 or higher according to CTCAE v5.0) that are definitely, probably, or possibly related to the treatment with Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan.

    Time frame: From the start of treatment until the end of the follow-up period (up to 2 years).

Secondary outcomes

  1. Frequency of UGT1A1*28 Allele

    Distribution and allelic frequency of the UGT1A1\*28 variant in the study population of breast cancer patients.

    Time frame: At baseline (once the genetic study is performed).

  2. Correlation Between Genetic Variants and Toxicity Severity

    Statistical association (using Odds Ratio) between the identified genetic variants (rs4148323, rs35350906, rs3064744, rs887829, rs111741722) and the severity of adverse events.

    Time frame: Analyzed at the completion of the 2-year study period.

  3. Predictive Model for Severe Toxicity

    Design of a predictive model based on genetic markers to anticipate the appearance of severe toxicities for each ADC studied.

    Time frame: At the end of the study (2 years).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Trita AS, Biafora A, Pichette Drapeau M, Weber P, Goossen LJ. Regiospecific ortho-C-H Allylation of Benzoic Acids. Angew Chem Int Ed Engl. 2018 Oct 26;57(44):14580-14584. doi: 10.1002/anie.201712520. Epub 2018 Mar 5. PubMed 29411933 ↗
  • Sony M, Antony J, McDermott O. The Impact of Healthcare 4.0 on the Healthcare Service Quality: A Systematic Literature Review. Hosp Top. 2023;101(4):288-304. doi: 10.1080/00185868.2022.2048220. Epub 2022 Mar 24. PubMed 35324390 ↗
  • Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortes J, O'Shaughnessy J, Dieras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PubMed 33882206 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared to ensure patient confidentiality and compliance with data protection regulations. Aggregate results will be available through scientific publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 17 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 13, 2026
StartActual
Jul 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07582887
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Responsible party
Isabel Blancas López Barajas (Dr., Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental) — Principal investigator
First posted
May 13, 2026
Start date
Jul 15, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 13, 2026

Study contacts

Isabel Blancas López-Barajas, MD, PhD
Contact
ensayosclinicosom.husc.sspa@juntadeandalucia.es
+34 958 023265

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion